^
    7ms
    CertainT-1: CER-1236 in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=18, Recruiting, CERo Therapeutics Holdings, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • CER-1236
    10ms
    CertainT-1: CER-1236 in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, CERo Therapeutics Holdings, Inc.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • CER-1236
    over2years
    Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentation. (PubMed, Mol Ther)
    We also show that activated CER-1236 T cells exhibit superior cross-presentation ability compared to conventional T cells, triggering E7-specific TCR-T responses in an HLA class I and TLR-2 dependent manner, thereby overcoming the limited antigen presentation capacity of conventional T cells. Therefore, CER-1236 T cells have the potential to achieve tumor control by eliciting both direct cytotoxic effects and indirect-mediated cross-priming.
    Journal
    |
    TLR2 (Toll Like Receptor 2)
    |
    EGFR mutation
    |
    CER-1236